AstraZeneca plc (LON:AZN) has received a consensus recommendation of “Hold” from the twenty-one brokerages that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is GBX 5,937.73 ($77.59).
Several equities analysts have commented on AZN shares. Barclays reissued an “overweight” rating and issued a GBX 6,600 ($86.24) price target (up previously from GBX 6,500 ($84.93)) on shares of AstraZeneca in a research report on Friday, August 10th. Cfra set a GBX 6,200 ($81.01) price target on shares of AstraZeneca and gave the company a “neutral” rating in a research report on Friday, November 9th. Credit Suisse Group reissued an “outperform” rating on shares of AstraZeneca in a research report on Monday, October 29th. Liberum Capital reissued a “hold” rating on shares of AstraZeneca in a research report on Friday, August 31st. Finally, JPMorgan Chase & Co. set a GBX 6,900 ($90.16) price target on shares of AstraZeneca and gave the company a “buy” rating in a research report on Friday, November 16th.
Shares of AZN stock opened at GBX 6,165 ($80.56) on Monday. AstraZeneca has a 52 week low of GBX 4,260 ($55.66) and a 52 week high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Liquidity
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.